THE PERIPHERAL BLOOD LEUKOCYTE PHENOTYPE IN PATIENTS WITH BREAST CANCER: EFFECT OF DOXORUBICIN/PACLITAXEL COMBINATION CHEMOTHERAPY

REFERENCES

• Norton L. Conceptual basis for advances in the systemic drug therapy of breast cancer. Semin. Oncol. 1997; 24: S11
   Google Scholar
• Apostolopoulos V., McKenzie I. F.C, Pietersz G. A. Breast cancer immunotherapy: Current status and future prospects. Immunol. Cell Biol. 1996; 74: 457
   PubMed Web of Science ®Google Scholar
• Eberlein T. J., Goedegebuure P. The Breast, K. I. Bland, E. M. Copeland, W. B. Saunders, Philadelphia 1998; 605
   Google Scholar
• Longo D. L., Hartmann L. C. Biological response modifiers in the management of patients with breast cancer. Breast Cancer Res. Treat. 1990; 16: 67
   PubMedGoogle Scholar
• McCoy J. L., Rucker R., Petros J. A. Cell-mediated immunity to tumorassociated antigens is a better predictor of survival in early stage breast cancer than stage, grade or lymph node status. Breast Cancer Res. Treat. 2000; 60: 227
   PubMedGoogle Scholar
• Berd D. Cancer vaccines: reborn or just recycled?. Semin. Oncol. 1998; 25: 605
   PubMedGoogle Scholar
• Clemons M., Leahy M., Valle J., Jayson G., Ranson M., Howell A. Review of recent trials of chemotherapy for advanced breast cancer:. The taxanes. Eur. J. Cancer 1997; 33: 2183
   PubMed Web of Science ®Google Scholar
• Moliterni A., Tarenzi E., Capri G., Terenziani M., Bertuzzi A., Grasselli G., Agresti R., Piotti P., Greco M., Salvadori B., Pilotti S., Lombardi F., Valagussa P., Bonaddonna G., Gianni L. Pilot study of primary chemotherapy with doxorubicin plus paclitaxel in women with locally advanced or operable breast cancer. Semin. Oncol. 1997; 24: S17
   PubMedGoogle Scholar
• Lee W. J., Chang K. J., Lee C. S., Chen K. M. Selective depression of T-lymphocyte subsets in gastric cancer patients: An implication of immunotherapy. J. Surg. Oncol. 1994; 55: 164
   Google Scholar
• Tancini G., Barni S., Rescaldani R., Fiorelli G., Viviani S., Lissoni P. Analysis of T helper and suppressor lymphocyte subsets in relation to the clinical stage of solid neoplasms. Oncology 1990; 47: 381
   PubMedGoogle Scholar
• Richner J., Ambinder E. P., Hoffmann K., Feuer E. J., Bekesi G. Number of helper T cells and phytohemagglutinin stimulation correlate in cancer patients. Cancer Immunol. Immun. 1991; 34: 138
   PubMedGoogle Scholar
• Melichar B., Touskova M., Solichova D., Kralickova P., Kopecky O. The phenotype of peripheral blood leukocytes and systemic immune activation in patients with primary and secondary liver tumors. Proc. A.A.C.R. 2000; 41: 621
   Google Scholar
• Head J. F., Elliott R. L., McCoy J. L. Evaluation of lymphocyte immunity in breast cancer patients. Breast Cancer Res. Treat. 1993; 26: 77
   PubMed Web of Science ®Google Scholar
• Ehrke J. M., Mihich E., Berd D., Mastrangelo M. J. Effects of anticancer drugs on the immune system in humans. Semin. Oncol. 1989; 16: 230
   PubMed Web of Science ®Google Scholar
• Mackall C. L., Fleisher T. A., Brown M. R., Andrich M. P., Chen C. C., Feurstein I. H., Magrath I. T., Wexler L. H., Dimitrov D. S., Gress R. E. Distinction between CD8+ and CD4+ T-cell pathways result in prolonged T-cell subset imbalance after intensive chemotherapy. Blood 1997; 89: 3700
   PubMed Web of Science ®Google Scholar
• Strender L. E., Blomgren H., Petrini B., Wasserman J., Forsgren M., Norberg R., Baral E., Wallgren A. Immunologic monitoring in breast cancer patients receiving postoperative adjuvant chemotherapy. Cancer 1981; 48: 1996
   PubMed Web of Science ®Google Scholar
• Newman G. H., Rees G. J.G., Jones R. S.J., Grove E. A., Preece A. W. Changes in helper and suppressor T lymphocytes following radiotherapy for breast cancer. Clin. Radiol. 1987; 38: 191
   PubMed Web of Science ®Google Scholar
• Petrini B., Wasserman J., Blomgren H., Rotstein S. T helper/suppressor ratios in chemotherapy and radiotherapy. Clin. Exp. Immunol. 1983; 53: 255
   PubMedGoogle Scholar
• Brunvand M. W., Collins C., Livingston R. B., Raghu G. Pneumocystis carinii pneumonia associated with profound lymphopenia and abnormal T-lymphocyte subset ratios during treatment for early-stage breast carcinoma. Cancer 1991; 67: 2407
   PubMedGoogle Scholar
• Cartei G., Sala P. G., Sanzari M., Ceschia V., Clocchiatti L., Sibau A., Dona S., Giovannoni M., Vigevani E. Reduced lymphocyte subpopulation in patients with advanced or disseminated melanoma. J. Am. Acad. Dermatol. 1993; 28: 738
   PubMedGoogle Scholar
• Roos M. T.L., Miedema F., Meinesz A. A.P., de Leeuw N. A.S.M., Pakker N. G., Lange J. M.A., Countinho R. A., Schellekens P. T.A. Low T cell reactivity to combined CD3 plus CD28 stimulation is predictive for progression to AIDS: correlation with decreased CD28 expression. Clin. Exp. Immunol. 1996; 105: 409
   PubMedGoogle Scholar
• Batliwalla F., Monteneiro J., Serrano D., Gregersen P. K. Oligoclonality of CD8+ T cells in health and disease: Aging, infection, or immune regulation?. Hum. Immunol. 1996; 48: 68
   PubMedGoogle Scholar
• Rotstein S., Blomgren H., Petrini B., Wasserman J., Nilsson B., Baral E. Blood lymphocyte counts with subset analysis in operable breast cancer. Cancer 1985; 56: 1413
   PubMedGoogle Scholar
• Ludwig C. U., Hartmann D., Landmann R., Wesp M., Rosenfelder G., Stucki D., Buser M., Obrecht J. P. Unaltered immunocompetence in patients with nondisseminated breast cancer at the time of diagnosis. Cancer 1985; 55: 1673
   PubMedGoogle Scholar
• Monteneiro J., Batliwalla F., Ostrer H., Gregersen P. K. Shortened telomeres in clonally expanded CD28-CD8+ T cells imply a replicative history that is distinct from their CD28+ CD8− counterparts. J. Immunol. 1996; 156: 3587
   PubMedGoogle Scholar
• Sephton S. E., Sapolsky R. M., Kraemer H. C., Spiegel D. Diurnal cortisol rhythm as a predictor of breast cancer survival. J. Natl. Cancer Inst. 2000; 92: 994
   PubMed Web of Science ®Google Scholar
• Yacyshyn M. B.B., Poppema S., Berg A., MacLean G. D., Reddish M. A., Meikle A., Longenecker B. M. CD69− and HLA-DR+ activation antigens on peripheral blood lymphocyte populations in metastatic breast and ovarian cancer patients: Correlations with survival following active specific immunotherapy. Int. J. Cancer 1995; 61: 470
   PubMedGoogle Scholar
• Saleh M. N., Goldman S. J., LoBuglio A. F., Beall A. C., Sabio H., McCord M. C., Minasian L., Alpaugh K., Weiner L. M., Munn D. H. CD16+ monocytes in patients with cancer: Spontaneous elevation and pharmacologic induction by recombinant human macrophage colony-stimulating factor. Blood 1995; 85: 2910
   PubMed Web of Science ®Google Scholar
• Lukac J., Kusic Z., Kordic M., Bolanca A. Natural killer cell activity, phagocytosis, and number of peripheral blood cells in breast cancer patients treated with tamoxifen. Breast Cancer Res. Treat. 1994; 29: 279
   PubMed Web of Science ®Google Scholar
• Nanbara S., Arinaga S., Akiyoshi T. Augmentation of the generation of lymphokine-activated killer cells after a single dose of mitomycin C in cancer patients. Cancer Immunol. Immun. 1989; 29: 237
   PubMed Web of Science ®Google Scholar
• Kuroi K., Sato Y., Yamaguchi Y., Toge T. Modulation of suppressor cell activities by cyclophosphamide in breast cancer patients. J. Clin. Lab. Anal. 1994; 8: 123
   PubMedGoogle Scholar
• Mullins D. W., Burger C. J., Elgert K. D. Paclitaxel enhances macrophage IL-12 production in tumor-bearing hosts through nitric oxide. J. Immunol. 1999; 162: 6811
   PubMed Web of Science ®Google Scholar
• Zaloudik J., Lauerova L., Janakova L., Talac R., Simickova M., Nekulova M., Mikulikova I., Kovarik J., Sheard M. Significance of pre-treatment immunological parameters in colorectal cancer patients with unresectable metastases to the liver. Hepato-Gastroenterol. 1999; 46: 220
   PubMedGoogle Scholar
• Sliwkowski M. X., Lofgren J. A., Lewis G. D., Hotaling T. E., Fendly B. M., Fox J. A. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin. Oncol. 1999; 26: 60
   PubMed Web of Science ®Google Scholar
• Slamon D., Leyland-Jones B., Shak S., Paton V., Bajamonde A., Fleming T., Eierman W., Wolter J., Baselga J., Norton L. Addition of Herceptin (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2+ /MBC) markedly increases anticancer activity: a randomized multinational controlled phase III trial. Proc. A.S.C.O. 1998; 17: 98
   Google Scholar
• Margolin K. A., Doroshow J. H., Akman S. A., Leong L. A., Morgan R., Raschko J., Somlo G., Dutcher J., Hawkworth K., Yonemoto L., Caliendo G., Cavasotto G. Phase I trial of interleukin-2 plus doxorubicin. J. Immunother. 1993; 14: 70
   Google Scholar